Agnieszka Sławomira Węgrzyn

Agnieszka Sławomira Węgrzyn

Auto-generated profile, based on publicly available information

Agnieszka Sławomira Węgrzyn

Łukasiewicz Research Network - PORT Polish Center for Technology Development, Bioengineering Group, Wroclaw, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2018 in Viruses
Verified
Journal Article
Open access
PDF file
POPiotr Orłowski
Piotr Orłowski
AKAndrzej Kowalczyk
Andrzej Kowalczyk
ETEmilia Tomaszewska
Emilia Tomaszewska
KRKatarzyna Ranoszek-Soliwoda
Katarzyna Ranoszek-Soliwoda
AWAgnieszka Węgrzyn
Agnieszka Węgrzyn
MKMałgorzata Krzyżowska
Małgorzata Krzyżowska
(1) Background: Tannic acid is a plant-derived polyphenol showing antiviral activity mainly because of an interference with the viral adsorption. In this work, we tested whether the modification of silver nanoparticles with tannic acid (TA-AgNPs) can provide a microbicide with additional adjuvant properties to treat genital herpes infection. (2) Methods: The mouse model of the vaginal herpes simplex virus 2 (HSV-2) infection was used to test immune responses after treatment of the primary infection with TA-AgNPs, and later, after a re-challenge with the virus. (3) Results: The mice treated intravaginally with TA-AgNPs showed better clinical scores and lower virus titers in the vaginal tissues soon after treatment. Following a re-challenge, the vaginal tissues treated with TA-AgNPs showed a significant increase in the percentages of IFN-gamma+ CD8+ T-cells, activated B cells, and plasma cells, while the spleens contained significantly higher percentages of IFN-gamma+ NK cells and effector-memory CD8+ T cells in comparison to NaCl-treated group. TA-AgNPs-treated animals also showed significantly better titers of anti-HSV-2 neutralization antibodies in sera; and (4) Conclusions: Our findings suggest that TA-AgNPs sized 33 nm can be an effective anti-viral microbicide to be applied upon the mucosal tissues with additional adjuvant properties enhancing an anti-HSV-2 immune response following secondary challenge.

19 January 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
AWAgnieszka S. Wegrzyn
Agnieszka S. Wegrzyn
AKAnna E. Kedzierska
Anna E. Kedzierska
AOAndrzej Obojski
Andrzej Obojski
Background: Regulatory T (Treg) cells have emerged as key players in the maintenance of immune homeostasis. Although significant progress has been made in recent years to define the Treg surface markers involved with or identifying their suppressive function, there remains much to be elucidated, and many questions persist. This study determined the expression of surface markers on human peripheral Treg cells and conventional T (Tconv) cells in a steady state and after activation to gain insight into their mechanism of action and more precisely characterize this regulatory population in humans.Methods: To screen Treg and Tconv cells, peripheral blood mononuclear cells (PBMCs) were isolated from volunteers, stained with a commercially available lyophilized antibody array comprising 371 surface antigens, and analyzed by flow cytometry. To compare Treg cells with activated Tconv cells, PBMCs were stimulated with PMA and further stained similar to freshly isolated cells.Results: Treg and Tconv cells were positive for 135 and 168 of the 371 antigens, respectively. Based on the frequency distribution, all of the most highly expressed markers identified were shared by both Treg and Tconv cells and participate in T cell activation, act as costimulatory and signaling molecules, or exhibit adhesion and migratory functions. Additionally, we identified several differences in marker expression between Treg and Tconv cells, with most found in the expression of co-stimulatory (ICOS, GITR, 4-1BB) and co-inhibitory (TIGIT, CTLA-4) molecules, as well as chemokine receptors (CXCR4, CXCR5, CCR4, CCR5, CCR7, CCR8, and CXCR7). Furthermore, post-activation expression of surface molecules identified molecules capable of discriminating Treg cells from activated Tconv cells (GITR, 4-1BB, TIGIT, CD120b, and CD39); however, almost all of these markers were also expressed in a small fraction of activated Tconv cells.Conclusions: These results offer insight into the biology of Tregs and contribute to their accurate identification and characterization in variety of immunological diseases as well as physiological processes

24 October 2018 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KKKatarzyna Kornicka
Katarzyna Kornicka
AŚAgnieszka Śmieszek
Agnieszka Śmieszek
AWAgnieszka Sławomira Węgrzyn
Agnieszka Sławomira Węgrzyn
MRMichael Röcken
Michael Röcken
KKrzysztof Marycz
Krzysztof Marycz
Endocrine disorders, including equine metabolic syndrome (EMS), are a serious issue in veterinary medicine and horse breeding. Furthermore, EMS was shown to affect the cytophysiological properties of adipose-derived stem cells, reducing their therapeutic potential. However, it was shown that those cells can be rejuvenated while using a combination of two chemicals: 5-azacytydine (AZA) and resveratrol (RES). In the present study, we decided to evaluate the immunomodulatory properties of AZA/RES-treated adipose-derived stem cells (ASC) isolated from EMS horses (ASCEMS). Thus, we co-cultured ASC with peripheral blood mononuclear cells (PBMC) and RAW264.7 macrophages. Most attention was placed on regulatory T lymphocytes (TREG), as well as the messenger RNA (mRNA) and protein levels of several cytokines (tumor necrosis factor α (TNF-α), interleukin (IL)-6, IL-10, and IL-1β). Moreover, we also investigated the expression of genes related to auto- and mitophagy in both PBMCs and ASCs. PBMCs were obtained from healthy and EMS-suffering individuals and were co-cultured with ASCs that were isolated from healthy and EMS horses cultured in control conditions and with AZA/RES. We discovered that cells treated with AZA/RES increase the TREG number while co-cultured with PBMCs. Moreover, the co-culture of PBMCs with AZA/RES-treated ASCEMS induced mitophagy in PBMCs. Furthermore, ASCEMS pre-treated with AZA/RES displayed anti-inflammatory properties, as decreased levels of TNF-α, nitric oxide (NO), and IL-6 were observed in those cells in comparison with their untreated counterparts in the co-culture with RAW264.7 macrophages. In summary, we demonstrated that ASCEMS treated with AZA/RES displayed increased anti-inflammatory properties, and was able to regulate and activate the TREG-related anti-inflammatory response.

5 October 2015 in Archivum Immunologiae et Therapiae Experimentalis
Verified
Journal Article
Open access
PDF file
JPJoanna P-D
Joanna P-D
AWAgnieszka Węgrzyn
Agnieszka Węgrzyn
ATAnna Turno-Kręcicka
Anna Turno-Kręcicka
MMMarta Misiuk-Hojło
Marta Misiuk-Hojło
Pars planitis is defined as an intermediate uveitis of unknown background of systemic disease with characteristic formations such as vitreous snowballs, snowbanks and changes in peripheral retina. The incidence of pars planitis varies 2.4–15.4 % of the uveitis patients. The pathogenesis of the disease is to be determined in future. Clinical and histopathological findings suggest an autoimmune etiology, most likely as a reaction to endogenous antigen of unknown source, with T cells predominant in both vitreous and pars plana infiltrations. T cells subsets play an important role as a memory-effector peripheral cell. Snowbanks are formed as an effect of post inflammatory glial proliferation of fibrous astrocytes. There is also a genetic predisposition for pars planitis by human leukocyte antigen and several other genes. A coexistence of multiple sclerosis and optic neuritis has been described in numerous studies. Epiretinal membrane, cataract, cystoid macular edema, retinal detachment, retinal vasculitis, neovascularization, vitreous peripheral traction, peripheral hole formation, vitreous hemorrhage, disc edema are common complications observed in pars planitis. There is a need to expand the knowledge of the pathogenic and immunologic background of the pars planitis to create an accurate pharmacological treatment.

1 July 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
AWAgnieszka S. Wegrzyn
Agnieszka S. Wegrzyn
BJBogdan Jakiela
Bogdan Jakiela
BRBeate Rückert
Beate Rückert
MJMarek Jutel
Marek Jutel
MAMübeccel Akdis
Mübeccel Akdis
CACezmi A. Akdis
Cezmi A. Akdis

1 November 2019 in Journal of Immunological Methods
Verified
Journal Article
Closed access
KSKatarzyna Skulska
Katarzyna Skulska
AWAgnieszka S. Wegrzyn
Agnieszka S. Wegrzyn
ACAnna Chełmońska-Soyta
Anna Chełmońska-Soyta
GCGrzegorz Chodaczek
Grzegorz Chodaczek